These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 21036490)
1. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490 [TBL] [Abstract][Full Text] [Related]
2. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817 [TBL] [Abstract][Full Text] [Related]
8. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Shields LB; Kadner R; Vitaz TW; Spalding AC Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500 [TBL] [Abstract][Full Text] [Related]
9. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182 [TBL] [Abstract][Full Text] [Related]
10. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978 [TBL] [Abstract][Full Text] [Related]
11. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029 [TBL] [Abstract][Full Text] [Related]
12. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997 [TBL] [Abstract][Full Text] [Related]
13. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662 [TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747 [TBL] [Abstract][Full Text] [Related]
17. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996 [TBL] [Abstract][Full Text] [Related]
18. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection. Friedman GK; Spiller SE; Harrison DK; Fiveash JB; Reddy AT J Pediatr Hematol Oncol; 2013 Apr; 35(3):e123-6. PubMed ID: 23425999 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]